Akari Therapeutics Delays Q2 Report: Impairment Charge, Price Drop & SEC Extension
Akari Therapeutics delays quarterly filing, faces a non‑cash impairment and seeks a 5‑day SEC extension—what this means for its anti‑inflammatory drug strategy and investor outlook.
2 minutes to read